Protein and peptide therapeutics /

Progress in Molecular Biology and Translational Science series, highlights new advances in the field, with this new volume presenting interesting chapters.Each chapter is written by an international board of authors.- Provides the latest information on protein and peptide therapeutics research- Offe...

Full description

Bibliographic Details
Corporate Author:	ScienceDirect (Online service)
Other Authors:	Teplow, David B. (Editor)
Format:	eBook
Language:	English
Published:	London, England : Academic Press, [2025]
Edition:	First edition.
Series:	Progress in molecular biology and translational science ; Volume 212.
Subjects:	Peptide antibiotics. Proteins. Antibiotiques peptidiques. Protéines. protein. Electronic books.
Online Access:	Connect to the full text of this electronic book

Table of Contents:

Front Cover
Progress in Molecular Biology and Translational Science
Copyright
Contents
Contributors
Preface
Chapter One: Targeting MYC with protein drugs
1 Introduction
2 The current cancer therapeutic arsenal: small molecule drugs
3 The next-generation cancer drug arsenal: protein therapeutics
4 The MYC/MAX/E-box network can go rogue
5 Transcription factors are intrinsically disordered structures
6 Omomyc, a model for protein drug development
7 ME47 and Mad: more potential protein drugs in the anti-cancer pipeline
8 Omomyc, Mad, ME 47, and MEF
9 The protein drug arsenal + small-molecule drug arsenal: the more, the merrier
10 Lipid nanoparticle delivery of drugs
11 War on cancer: the next generation
Acknowledgments
References
Chapter Two: Peptide-based inhibitors of epigenetic proteins
1 Introduction
2 Writers
3 Inhibitors of DNA methyltransferases
4 Inhibitors of histone lysine methyltransferases
5 Inhibitors of histone lysine acetyltransferases
6 Inhibitors of protein arginine methyltransferases
7 Inhibitors of peptidyl arginine deiminases
8 Inhibitors of O-GlcNAc transferase
9 Erasers
10 Inhibitors of ten-eleven translocation enzymes
11 Inhibitors of histone lysine demethylases
12 Inhibitors of histone lysine deacetylases
13 Readers
14 Inhibitors of methyllysine readers
15 Inhibitors of acyllysine readers
16 Conclusion and outlook
Acknowledgements
References
Chapter Three: Membrane-active peptides for anticancer therapies
1 Introduction
2 Membrane-active peptides
3 Formulation development for peptide therapeutics
4 Peptide therapeutics in oncology
5 Development of membrane-active anticancer peptides
6 Conclusion
Conflict of interest
References.
Chapter Four: Peptide pharmacology: Pioneering interventions for alcohol use disorder
1 Introduction to alcohol use disorder (AUD)
2 Neurobiology of alcohol addiction
2.1 Brain circuits involved in addiction
2.2 Role of neurotransmitters in reward processing
3 Peptides as therapeutic agents
3.1 Opioid peptides and AUD
3.2 Corticotropin-releasing factor (CRF) peptides
3.3 Neuropeptide Y (NPY) and related peptides
4 Peptides targeting glutamate signaling
5 Clinical translation
6 Future directions and perspectives
7 Conclusion
References
Chapter Five: Peptides on patrol: Carrier systems for targeted delivery
1 Introduction
2 Identification and synthesis of peptides
3 Different carrier-mediated delivery of peptides
3.1 Conjugation with nanocarriers
3.2 Conjugation with therapeutics (peptide drug conjugates)
3.3 Transport of peptide via different routes
3.3.1 Oral delivery
3.3.2 Transdermal
3.3.3 Nasal delivery
3.3.4 Parenteral
3.4 Application of peptides in diseases
3.4.1 In cancer
3.4.2 In neurological disorders
3.5 Vaccines
4 Clinical and pre-clinical studies
5 Challenges
6 Conclusion and future prospects
Acknowledgment
References
Chapter Six: Daptomycin: Mechanism of action, mechanisms of resistance, synthesis and structure-activity relationships
1 Introduction
2 Structure and biosynthesis of Daptomycin
3 Key physical properties
3.1 Calcium binding and ionization state
3.2 Conformational change and 3-D structure
3.3 Daptomycin fluorescence
3.4 Aggregation of Daptomycin in solution
4 The targets of Daptomycin
4.1 Phosphatidylglycerol
4.2 Lipid II/C55P/C55PP
4.3 Possible protein targets
4.3.1 Daptomycin-binding proteins
4.3.2 Binding to Usp2
5 The mechanism of action of Daptomycin.
5.1 Lipoteichoic acid biosynthesis
5.2 Lipid extraction
5.3 Accumulation of reactive oxygen species
5.4 Membrane depolarization
5.4.1 Early studies with bacteria
5.4.2 Dap oligomerization in membranes
5.4.3 Daptomycin pore formation and translocation across membranes
5.5 Reorganization of the membrane and inhibition of peptidoglycan synthesis
5.6 Concluding comments regarding Daptomycin's mechanism of action
6 Daptomycin resistance mechanisms
6.1 Multiple peptide resistance factor
6.2 cls
6.3 PG synthase
6.4 LiaFSR
6.5 yyCG (walKR)
6.6 Dlt operon and graRS
6.7 Phospholipid shedding
6.8 Summary of resistance mechanisms
7 Chemical synthesis of Daptomycin
7.1 The Li group's synthesis of Daptomycin
7.2 The Taylor group's solid phase synthesis of Daptomycin
7.3 Xu et al.'s synthesis of Daptomycin
7.4 Moreira and Taylor's synthesis of Daptomycin
8 Methods for preparing Daptomycin analogues
8.1 Semi-synthetic routes to Daptomycin analogues
8.1.1 N-terminal modification via acylation
8.1.2 Orn modification via acylation and alkylation
8.1.3 Amino acid substitution at position 1 via deacylation/Edman degradation
8.1.4 Modification of Trp1 using prenyltransferases
8.1.5 Modification of kynurenine-13 via regioselective reductive amination
8.2 Methods for preparing Daptomycin analogues that allow for amino acid substitutions at most or all positions
8.2.1 Combinatorial biosynthetic approach Daptomycin analogues
8.2.2 Chemoenzymatic approach to Daptomycin analogues
9 Structure-activity relationships
9.1 N-terminal modification
9.2 Alanine scans
9.3 Position 1
9.4 Position 2
9.5 Position 3
9.6 Position 4 and the ester bond
9.7 Position 5
9.8 Position 6
9.9 Positions 8 and 11
9.10 The DXDG motif (positions 7-10)
9.11 Position 12.
9.12 Position 13
9.13 Stereochemistry
9.13.1 Effect of the stereochemical configuration of individual residues on Daptomycin activity
9.13.2 Effect of the overall stereochemical configuration of Daptomycin on activity
9.14 Summary of structure-activity relationships studies
10 Daptomycin derivatives with activity against G- bacteria
11 Concluding remarks
References
Chapter Seven: Delivery of protein therapeutics and vaccines using their multivalent complexes with synthetic polyelectrolytes
1 Introduction
2 Polyelectrolytes and their spontaneous self-assembly with proteins
3 Polyelectrolytes as delivery vehicles with inherent biological activity
3.1 Polyelectrolytes as vaccine adjuvants and delivery vehicles
3.2 Other biologically active polyelectrolytes
4 Polyelectrolytes designed as inert protein modifying agents
4.1 Polyelectrolytes as PEGylation agents
4.2 PEGylated complexes based on ionic block and graft copolymers
4.3 PEGylated ternary polyanion-protein-polycation complexes
4.4 PEGylated complexes based on dendritic copolymers
4.5 PEGylated complexes with 'mobile' links
5 Stability of non-covalently bound protein-polyelectrolyte complexes
6 Conclusion
References
Chapter Eight: Delivery of therapeutic proteins to ocular tissues: Barriers, approaches, regulatory considerations and future perspectives
1 Introduction
1.1 The significance of ocular therapeutics
1.2 Overview of therapeutic proteins in ophthalmology
2 Anatomy and physiology
2.1 Structure of eye
2.2 Obstacles to drug delivery
2.3 Routes of drug absorption
3 Therapeutic proteins used in the field of ophthalmology
3.1 Categories of therapeutic proteins
3.2 Action mechanisms
3.3 Present clinical utilizations
4 Progress in ocular delivery systems.
4.1 Strategies for developing a formulation
4.2 Pharmaceutical transportation methods
4.2.1 Nanotechnology
4.2.2 Hydrogels
4.2.3 Microneedles are small, needle-like structures
4.3 Novel drug delivery systems
4.3.1 Liposomes
4.3.2 Dendrimers
A brief overview
4.3.3 Nanoparticles made of polymers
5 Barriers in the administration of therapeutic proteins to the eye
5.1 Lacrymal film
5.2 The corneal epithelium: The outermost layer of cells covering the cornea
5.3 The blood-retinal barrier
5.4 Stability and bioavailability
5.5 Immunogenicity
5.6 Adherence of the patient to prescribed medical treatment
6 Approaches to address delivery obstacles
6.1 Improving the capacity of a substance to pass through a barrier
6.2 Extended-release formulations
6.3 Methods for delivery without penetration
6.4 Methods for precise delivery
7 Regulatory and commercialization considerations
7.1 Regulatory pathways
7.2 Market considerations
7.3 Copyright
8 Prospects for the future
8.1 Emerging technologies
8.2 Predictive modeling and simulation
8.3 Promising advances
References
Chapter Nine: Peptidomimetics design and characterization: Bridging experimental and computer-based approaches
1 Introduction
1.1 Clinical potential and therapeutic applications of peptidomimetics
1.2 Peptidomimetics classification and chemical modifications
1.3 Peptidomimetics design in the machine learning era
1.4 Peptidomimetic conformational search and binding free energy calculation
1.5 Computational tools for peptidomimetic permeability analysis
1.6 The molecular landscape: experimental characterization of peptidomimetics
1.7 Concluding remarks and future prospective
Acknowledgements
References
Chapter Ten: Vaccines reimagined: The peptide revolution in disease prevention.